Sanofi is eyeing up global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing ...

Sanofi has launched an educational campaign to raise awareness about smoldering multiple sclerosis (MS), the lesser known of two processes that cause the neurological disease. Unlike acute MS ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

The frexalimab result is a boost to Sanofi’s ambitions in MS, particularly after its lead drug candidate tolebrutinib, an oral BTK inhibitor, was placed on a clinical hold by the FDA while a ...

Brad Lightcap, COO, OpenAI "We believe AI can accelerate drug development, bringing new treatments to patients more quickly. This first product from our collaboration with Sanofi and Formation Bio is ...

Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing ...